Bayer Backs Kerendia To Be A Blockbuster
High Hopes For Nubeqa Too
Just approved In US for chronic kidney disease in patients with type 2 diabetes, Kerendia is going to be an important new treatment option, according to Bayer pharma head Stefan Oelrich, who was speaking as the Leverkusen-headquartered group unveiled a decent set of sales figures for the second quarter.
You may also be interested in...
Bayer's Faith In Pharma Pipeline Paying Off
The German major has presented the latest developments in the ongoing transformation of its pharmaceuticals business, starting with the prostate cancer therapy Nubeqa which Bayer believes will be a €3bn drug, way up on its earlier estimate of €1bn.
Bayer Pharma R&D Head Tackles Challenge Of Prioritizing Promising Assets
Nearly a year into the job, research chief Christian Rommel tells Scrip he is impressed with Bayer's arm's length approach to running acquired firms like AskBio and BlueRock and the task ahead is to deliver on the potential they offer, while getting later-stage projects across the approvals finishing line.
J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals
Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals.